Apogee Therapeutics (APGE) News Today $27.94 -2.08 (-6.93%) (As of 12/29/2023 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineApogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Recommendation of "Buy" by Brokeragesmarketbeat.com - December 31 at 6:19 AMApogee Therapeutics (NASDAQ:APGE) Stock Price Up 2.5%americanbankingnews.com - December 31 at 2:38 AMCritical Survey: Apogee Therapeutics (NASDAQ:APGE) and Sutro Biopharma (NASDAQ:STRO)americanbankingnews.com - December 26 at 1:40 AMApogee Therapeutics (NASDAQ:APGE) Stock Price Up 6.6%americanbankingnews.com - December 24 at 3:02 AMApogee Therapeutics (NASDAQ:APGE) Hits New 12-Month High at $25.85americanbankingnews.com - December 23 at 4:30 AMApogee Therapeutics Stock (NASDAQ:APGE), Analyst Ratings, Price Targets, Predictionsbenzinga.com - December 22 at 3:26 PMApogee Therapeutics Stock (NASDAQ:APGE) Dividends: History, Yield and Datesbenzinga.com - December 21 at 12:56 PMApogee Therapeutics (NASDAQ:APGE) Receives New Coverage from Analysts at BTIG Researchamericanbankingnews.com - December 21 at 3:42 AMApogee Therapeutics (NASDAQ:APGE) Coverage Initiated at BTIG Researchmarketbeat.com - December 20 at 7:10 AMLexington diabetes drug, device maker files for IPO — a rarity in 2023bizjournals.com - December 15 at 1:36 PMApogee Therapeutics, Inc.: Outshining Lebrikizumab with APG777’s Enhanced Efficacy and Quarterly Dosing Advantagemarkets.businessinsider.com - November 28 at 11:14 PMWe Think Apogee Therapeutics (NASDAQ:APGE) Can Easily Afford To Drive Business Growthfinance.yahoo.com - November 21 at 6:25 PMApogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progressfinance.yahoo.com - November 15 at 8:59 AMApogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 13 at 8:20 AMApogee Therapeutics Inc APGEmorningstar.com - November 8 at 8:59 AMA handful of biotechs have finally held IPOs. Will more follow?bizjournals.com - November 2 at 8:00 AMApogee Therapeutics to Participate in Upcoming November Investor Conferencesfinance.yahoo.com - October 30 at 9:34 AMApogee Therapeutics Announces IPO Of 15.625 Mln Shares To Be Priced Between $15.00 And $17.00/Sharefinanznachrichten.de - October 24 at 11:58 PMApogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congressfinance.yahoo.com - September 27 at 10:00 AMApogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Recommendation of "Buy" from Analystsmarketbeat.com - September 22 at 8:12 AMA biotech holds a $250M IPO, stoking flames of hope for industry watchersbizjournals.com - September 15 at 5:59 PMApogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Dayfinance.yahoo.com - September 14 at 10:19 AMQ3 2023 EPS Estimates for Apogee Therapeutics, Inc. (NASDAQ:APGE) Lifted by Analystmarketbeat.com - August 31 at 6:11 AMParagon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeuticsfinance.yahoo.com - August 29 at 6:03 PMApogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 28 at 10:01 AMApogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosingseekingalpha.com - August 22 at 8:14 AMApogee Therapeutics appoints Mark C. Mckenna as Chairman of its boardseekingalpha.com - August 21 at 3:52 PMApogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Boardfinance.yahoo.com - August 21 at 9:56 AMApogee Therapeutics, Inc.'s Quiet Period To Expire on August 23rd (NASDAQ:APGE)marketbeat.com - August 16 at 1:32 AMApogee Therapeutics, Inc. (NASDAQ:APGE) Forecasted to Post Q2 2023 Earnings of ($0.51) Per Sharemarketbeat.com - August 10 at 6:48 AMApogee Therapeutics (NASDAQ:APGE) Coverage Initiated at TD Cowenmarketbeat.com - August 8 at 8:42 AMApogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseasesfinance.yahoo.com - August 7 at 8:19 AMApogee Therapeutics, Turnstone Biologics See Activist Actionmsn.com - August 4 at 10:54 PMApogee Therapeutics to Participate in Upcoming August Investor Conferencesfinance.yahoo.com - August 2 at 7:55 AMApogee Therapeutics Inc.barrons.com - July 28 at 11:32 PMApogee Therapeutics Inc (APGE)investing.com - July 20 at 12:59 AMApogee Therapeutics Rings the Closing Bellnasdaq.com - July 19 at 7:59 PMApogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Sharesfinance.yahoo.com - July 18 at 6:17 PM Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address APGE Media Mentions By Week APGE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APGE News Sentiment▼0.650.84▲Average Medical News Sentiment APGE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APGE Articles This Week▼41▲APGE Articles Average Week Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KYMR News Today SRRK News Today RLAY News Today INBX News Today VIR News Today VCEL News Today BCRX News Today TALS News Today AUTL News Today ADMA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:APGE) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.